At 16:00 CET on Wednesday Feb 23, 2022, Orphazyme will meet with the European Medicines Agency’s (EMA) special committee, the CHMP, to give a so-called ”oral explanation.”
The biotech company has been summoned by the EMA in connection with the approval process of Orphazyme’s biggest drug hope, its candidate arimoclomol, a potential treatment for neurodegenerative disease Niemann-Pick type C (NPC).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology brings in head of EMEA region from Coloplast
The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region.
Dupixent could dominate pediatric eczema market for up to a decade, analysis finds
Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.
FDA advisors support approval for Ferring's intestinal infection medicine
All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection.
Pharmacosmos expects massive growth in four years
The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame.
The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project
Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms.
Chief Business Officer 
LIMS Super User for Operations at ALK 
CMC Writer 
Nordic Key Account Manager, Hollister & Dansac 
Vice President, Medical Affairs 
Product specialist in Cardio Rhythm Management, Zealand 
Pharmacovigilance & Regulatory Officer 
Pharmacovigliance (Associate) Director or Senior Specialist 
Lab Manager 
Product specialist 
Ambitious Business Relationship Manager for the Danish Medicines Agency 
Scientist Radiochemistry